# Gracell Biotechnologies Inc. (GRCL)

Source: https://www.quantisnow.com/company/GRCL
Generated: 2026-11-11T11:33:35.905Z

- Ticker: GRCL
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: https://www.gracellbio.com

## About

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

## Latest GRCL news and filings

- 2024-03-04 17:22 UTC [SEC Form 15-12G filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-gracell-biotechnologies-inc-5312646)
- 2024-02-28 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-gracell-biotechnologies-inc-5298398)
- 2024-02-28 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-gracell-biotechnologies-inc-5298360)
- 2024-02-26 22:28 UTC [SEC Form POS AM filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-gracell-biotechnologies-inc-5292951)
- 2024-02-26 22:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-gracell-biotechnologies-inc-5292948)
- 2024-02-26 22:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-gracell-biotechnologies-inc-5292938)
- 2024-02-26 22:26 UTC [SEC Form POS AM filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-gracell-biotechnologies-inc-5292937)
- 2024-02-22 14:31 UTC [Market Chatter] [Stifel Downgrades Gracell Biotechnologies to Hold, Lowers Price Target to $10.25](https://www.quantisnow.com/insight/stifel-downgrades-gracell-biotechnologies-to-hold-lowers-price-target-to-5283464)
- 2024-02-22 14:01 UTC [SEC Form 25-NSE filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-gracell-biotechnologies-inc-5283347)
- 2024-02-22 13:50 UTC [SEC Form 6-K] [SEC Form 6-K filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gracell-biotechnologies-inc-5283237)
- 2024-02-22 13:45 UTC [Gracell Biotechnologies Acquisition Completed](https://www.quantisnow.com/insight/gracell-biotechnologies-acquisition-completed-5283218)
- 2024-02-20 13:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gracell-biotechnologies-inc-5273596)
- 2024-02-20 12:55 UTC [Market Chatter] [Gracell Biotechnologies Shareholders Approve AstraZeneca Merger Agreement](https://www.quantisnow.com/insight/gracell-biotechnologies-shareholders-approve-astrazeneca-merger-agreement-5273355)
- 2024-02-20 12:45 UTC [Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement](https://www.quantisnow.com/insight/gracell-biotechnologies-announces-shareholders-approval-of-merger-agreement-5273327)
- 2024-02-14 22:01 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-gracell-biotechnologies-inc-amendment-5264767)
- 2024-02-14 13:20 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-gracell-biotechnologies-inc-amendment-5259639)
- 2024-02-14 13:00 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-gracell-biotechnologies-inc-5259549)
- 2024-02-13 22:26 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-gracell-biotechnologies-inc-amendment-5257683)
- 2024-02-13 22:00 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Gracell Biotechnologies Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-gracell-biotechnologies-inc-amendment-5256057)
- 2024-01-30 11:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gracell-biotechnologies-inc-5215405)
- 2024-01-29 12:04 UTC [Market Chatter] [Gracell Biotechnologies Announces FDA Clearance For Its Investigational New Drug Application For Phase 1 Trial Of GC012F In The U.S. For The Early-line Treatment Of Multiple Myeloma](https://www.quantisnow.com/insight/gracell-biotechnologies-announces-fda-clearance-for-its-investigational-new-drug-5212401)
- 2024-01-29 12:00 UTC [Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma](https://www.quantisnow.com/insight/gracell-biotechnologies-announces-fda-clearance-of-ind-application-for-phase-5212338)
- 2024-01-23 13:19 UTC [Market Insight] [Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment](https://www.quantisnow.com/insight/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-5200395)
- 2024-01-17 21:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gracell-biotechnologies-inc-5191662)
- 2024-01-08 21:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gracell-biotechnologies-inc-5176408)
- 2024-01-05 15:26 UTC [Market Insight] [With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs](https://www.quantisnow.com/insight/with-its-sale-to-astrazeneca-gracell-blazes-exit-trail-for-5172481)
- 2023-12-27 17:27 UTC [Market Chatter] [Wells Fargo Downgrades Gracell Biotechnologies to Equal-Weight, Announces $10 Price Target](https://www.quantisnow.com/insight/wells-fargo-downgrades-gracell-biotechnologies-to-equal-weight-announces-10-price-5155960)
- 2023-12-27 09:31 UTC [Market Chatter] [Piper Sandler Downgrades Gracell Biotechnologies to Neutral, Announces $10 Price Target](https://www.quantisnow.com/insight/piper-sandler-downgrades-gracell-biotechnologies-to-neutral-announces-10-price-5155424)
- 2023-12-27 08:28 UTC [Market Insight] [Investor Sentiment Improves; Dow Jumps Over 150 Points](https://www.quantisnow.com/insight/investor-sentiment-improves-dow-jumps-over-150-points-5155416)
- 2023-12-26 19:43 UTC [Market Insight] [Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher](https://www.quantisnow.com/insight/nasdaq-surges-75-points-inspira-technologies-shares-spike-higher-5154817)
- 2023-12-26 18:48 UTC [Market Insight] [Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session](https://www.quantisnow.com/insight/why-rayzebio-shares-are-trading-higher-by-100-here-are-5154778)
- 2023-12-26 17:31 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-intraday-session-5154723)
- 2023-12-26 17:20 UTC [Market Insight] [Crude Oil Rises Over 3%; US Home Prices Increase In October](https://www.quantisnow.com/insight/crude-oil-rises-over-3-us-home-prices-increase-in-5154713)
- 2023-12-26 17:17 UTC [Market Chatter] [BTIG Downgrades Gracell Biotechnologies to Neutral](https://www.quantisnow.com/insight/btig-downgrades-gracell-biotechnologies-to-neutral-5154711)
- 2023-12-26 15:29 UTC [Market Chatter] [HC Wainwright & Co. Downgrades Gracell Biotechnologies to Neutral, Lowers Price Target to $10](https://www.quantisnow.com/insight/hc-wainwright-co-downgrades-gracell-biotechnologies-to-neutral-lowers-price-5154581)
- 2023-12-26 15:10 UTC [Market Insight] [Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies](https://www.quantisnow.com/insight/health-care-company-astrazeneca-announces-acquisition-of-gracell-biotechnologies-5154571)
- 2023-12-26 13:23 UTC [Market Chatter] [Gracell Biotechnologies shares are trading higher after the company announced that it entered into a definitive agreement to be acquired by AstraZeneca for approximately $1.2 billion.](https://www.quantisnow.com/insight/gracell-biotechnologies-shares-are-trading-higher-after-the-company-announced-5154394)
- 2023-12-26 13:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Gracell Biotechnologies Inc.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-gracell-biotechnologies-inc-5154383)
- 2023-12-26 13:07 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-pre-market-session-5154372)
- 2023-12-26 13:00 UTC [Market Insight] [Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-sentage-holdings-shares-are-trading-lower-by-5-here-5154347)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GRCL
- Earnings history: https://www.quantisnow.com/earnings/GRCL
- Dividend history: https://www.quantisnow.com/dividends/GRCL
- Insider transactions: https://www.quantisnow.com/insiders/GRCL
- Options chain: https://www.quantisnow.com/options/GRCL
- SEC 8-K filings only: https://www.quantisnow.com/company/GRCL/8-k
- RSS and alerts for GRCL: https://www.quantisnow.com/docs/rss-feeds.md